Sinna Pilgaard Ulrichsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sinna Pilgaard Ulrichsen has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Mette Nørgaard
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
6 shared publications - Christian Fynbo Christiansen
Department of Clinical Epidemiology, Aarhus University Hospital , Aarhus
5 shared publications - Carolyn E. Cesta
Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden
3 shared publications - Helga Zoega
Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland
3 shared publications - Jacqueline M. Cohen
Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
3 shared publications - Kari Furu
Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
3 shared publications
Latest Publications
- Open Access
- 21 November 2025
- Published by Wiley in International Journal of Cancer
- Vol. 158 (8) , 2111-2119
Body mass index and colorectal cancer recurrence and mortality: A nationwide cohort study in Denmark
Obesity may exacerbate colorectal cancer (CRC) prognosis, yet previous studies have shown inconsistent findings due to methodological limitations. In this nationwide cohort study, we investigated the association between body mass index (BMI) on CRC recurrence and mortality, while examining the influence of demographic, clinical, and socioeconomic characteristics. From the Danish Colorectal Cancer Group database and population‐based registries, we assembled a cohort of stage I–III CRC patients who underwent curative intent surgery between 2002 and 2020. We identified 5‐year CRC recurrence and mortality using validated algorithms and registries. We estimated cumulative incidence functions (CIFs) and applied Cox regression modeling BMI via splines and categorically. We examined synergistic effects via stratification and interaction analyses. Median follow‐up was 4.4 years for recurrence and 4.5 years for mortality; 5877 patients experienced CRC recurrence (CIF = 18.4%) and 6568 died (CIF = 21.8%). BMI was not associated with the recurrence of colon or rectal cancer. Underweight (BMI 35 kg/m 2 ) were associated with increased mortality, especially for rectal cancer. For rectal cancer, class II–III obesity was associated with excess mortality, particularly in younger patients (30–50 years) and males. For colon and rectal cancer, male sex, young age and comorbidities interacted to increase mortality in patients with underweight, whereas short education and smoking did so for colon cancer, and alcohol consumption for rectal cancer. Type 2 diabetes had minor influence on the associations. BMI‐related mortality in CRC may be modified by demographic, clinical and socioeconomic characteristics. Targeted interventions considering the high‐risk subgroups may help improve CRC outcomes.
- 21 November 2025
- Published by Wiley in International Journal of Cancer
- Vol. 158 (8) , 2111-2119
Open AccessBody mass index and colorectal cancer recurrence and mortality: A nationwide cohort study in Denmark
Obesity may exacerbate colorectal cancer (CRC) prognosis, yet previous studies have shown inconsistent findings due to methodological limitations. In this nationwide cohort study, we investigated the association between body mass index (BMI) on CRC recurrence and mortality, while examining the influence of demographic, clinical, and socioeconomic characteristics. From the Danish Colorectal Cancer Group database and population‐based registries, we assembled a cohort of stage I–III CRC patients who underwent curative intent surgery between 2002 and 2020. We identified 5‐year CRC recurrence and mortality using validated algorithms and registries. We estimated cumulative incidence functions (CIFs) and applied Cox regression modeling BMI via splines and categorically. We examined synergistic effects via stratification and interaction analyses. Median follow‐up was 4.4 years for recurrence and 4.5 years for mortality; 5877 patients experienced CRC recurrence (CIF = 18.4%) and 6568 died (CIF = 21.8%). BMI was not associated with the recurrence of colon or rectal cancer. Underweight (BMI 35 kg/m 2 ) were associated with increased mortality, especially for rectal cancer. For rectal cancer, class II–III obesity was associated with excess mortality, particularly in younger patients (30–50 years) and males. For colon and rectal cancer, male sex, young age and comorbidities interacted to increase mortality in patients with underweight, whereas short education and smoking did so for colon cancer, and alcohol consumption for rectal cancer. Type 2 diabetes had minor influence on the associations. BMI‐related mortality in CRC may be modified by demographic, clinical and socioeconomic characteristics. Targeted interventions considering the high‐risk subgroups may help improve CRC outcomes.
- Open Access
- 28 January 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (7) , 1547-1560
Risk and prognosis of posttransplant lymphoproliferative disease in Epstein-Barr virus–seronegative kidney transplant recipients — an observational cohort study from Norway and western Denmark
- 28 January 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (7) , 1547-1560
Open AccessRisk and prognosis of posttransplant lymphoproliferative disease in Epstein-Barr virus–seronegative kidney transplant recipients — an observational cohort study from Norway and western Denmark
- Open Access
- 19 December 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 50, 101189
Occurrence, mortality, and economic burden of brain disorders in Denmark, 2015–2021: a population-based cohort study
- 19 December 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 50, 101189
Open AccessOccurrence, mortality, and economic burden of brain disorders in Denmark, 2015–2021: a population-based cohort study
- 16 December 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (2) , 360-371
A prospective study of male physical activity and fecundability
STUDY QUESTION: To what extent is male physical activity (PA) associated with fecundability (per-cycle probability of conception)? SUMMARY ANSWER: Preconception levels of vigorous, moderate, or total PA were not consistently associated with fecundability across Danish and North American cohorts, but there was suggestive evidence that bicycling with a ‘soft, comfort seat’ was associated with reduced fecundability in both cohorts, especially among males with greater BMI. WHAT IS KNOWN ALREADY: Among males, some studies indicate that moderate PA might improve fertility, whereas vigorous PA, especially bicycling, might be detrimental. STUDY DESIGN, SIZE, DURATION: We assessed the association between male PA and fecundability among couples participating in two preconception cohort studies: SnartForaeldre.dk (SF) in Denmark (2011–2023) and Pregnancy Study Online (PRESTO) in North America (2013–2024). We restricted analyses to 4921 males (1088 in SF and 3833 in PRESTO) who had been trying to conceive with their partners for ≤6 cycles at enrollment. PARTICIPANTS/MATERIALS, SETTING, METHODS: At baseline, male partners reported data on medical history, lifestyle, behavioral, anthropometric factors, and their PA levels using different instruments [SF: International Physical Activity Questionnaire (IPAQ); PRESTO: average annual hours/week and type]. Both cohorts included additional questions on bicycling (frequency, bike seat type). After linking couple data at baseline, the female partner completed follow-up questionnaires to update their pregnancy status every 8 weeks for 12 months or until conception, whichever occurred first. We used proportional probabilities regression models to estimate fecundability ratios (FRs) and 95% CIs, controlling for potential confounders. MAIN RESULTS AND THE ROLE OF CHANCE: Average hours/week of vigorous PA, moderate PA, and total metabolic equivalents of task were generally inversely associated with fecundability in SF, but not PRESTO. While there was little association with bicycling overall in either cohort, we observed an inverse association for bicycling using a ‘soft, comfort seat’ (≥3 vs 0 h/week: SF: FR = 0.75, 95% CI: 0.53–1.05; PRESTO: FR = 0.81, 95% CI: 0.62–1.07) but not a ‘hard, racing-style seat’ (≥3 vs 0 h/week: SF: FR = 1.16, 95% CI: 0.95–1.41; PRESTO: FR = 1.06, 95% CI: 0.89–1.28). Among males with BMI ≥25 kg/m2, associations with bicycling using a ‘soft, comfort seat’ were similar or stronger (≥3 vs 0 h/week: SF: FR = 0.75, 95% CI: 0.45–1.24; PRESTO: FR = 0.73, 95% CI: 0.52–1.03). LIMITATIONS, REASONS FOR CAUTION: Misclassification of PA was likely the most important study limitation because we ascertained PA only once at enrollment using different instruments in each cohort. We would expect misclassification of PA to be non-differential given the prospective study design. Additional weaknesses include the narrow range of PA levels evaluated, reduced precision when stratifying the data by selected covariates, and limited generalizability due to the large percentage of non-Hispanic White participants and restriction of the cohort to pregnancy planners. WIDER IMPLICATIONS OF THE FINDINGS: Further evaluation of the potential deleterious effects of bicycling on male fertility, with additional consideration of the influence of bike seat type and BMI, may be warranted. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by NICHD Grants R21-HD072326, R01-HD086742, R01 HD105863, and R03-HD094117. These funding bodies had no involvement in the: study design; collection, analysis, and interpretation of data; writing of the report; or decision to submit the article for publication. L.A.W. serves as a paid consultant for AbbVie, Inc. and the Bill and Melinda Gates Foundation. She also receives in-kind donations for primary data collection in Pregnancy Study Online (PRESTO) from Swiss Precision Diagnostics (home pregnancy tests) and Kindara.com (fertility apps). All of these relationships are for work unrelated to this manuscript. M.L.E. is an advisor for and holds stock in Legacy, Doveras, VSeat, Hannah, Illumicell, HisTurn, & Next. The other authors have no competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.
- 16 December 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (2) , 360-371
A prospective study of male physical activity and fecundability
STUDY QUESTION: To what extent is male physical activity (PA) associated with fecundability (per-cycle probability of conception)? SUMMARY ANSWER: Preconception levels of vigorous, moderate, or total PA were not consistently associated with fecundability across Danish and North American cohorts, but there was suggestive evidence that bicycling with a ‘soft, comfort seat’ was associated with reduced fecundability in both cohorts, especially among males with greater BMI. WHAT IS KNOWN ALREADY: Among males, some studies indicate that moderate PA might improve fertility, whereas vigorous PA, especially bicycling, might be detrimental. STUDY DESIGN, SIZE, DURATION: We assessed the association between male PA and fecundability among couples participating in two preconception cohort studies: SnartForaeldre.dk (SF) in Denmark (2011–2023) and Pregnancy Study Online (PRESTO) in North America (2013–2024). We restricted analyses to 4921 males (1088 in SF and 3833 in PRESTO) who had been trying to conceive with their partners for ≤6 cycles at enrollment. PARTICIPANTS/MATERIALS, SETTING, METHODS: At baseline, male partners reported data on medical history, lifestyle, behavioral, anthropometric factors, and their PA levels using different instruments [SF: International Physical Activity Questionnaire (IPAQ); PRESTO: average annual hours/week and type]. Both cohorts included additional questions on bicycling (frequency, bike seat type). After linking couple data at baseline, the female partner completed follow-up questionnaires to update their pregnancy status every 8 weeks for 12 months or until conception, whichever occurred first. We used proportional probabilities regression models to estimate fecundability ratios (FRs) and 95% CIs, controlling for potential confounders. MAIN RESULTS AND THE ROLE OF CHANCE: Average hours/week of vigorous PA, moderate PA, and total metabolic equivalents of task were generally inversely associated with fecundability in SF, but not PRESTO. While there was little association with bicycling overall in either cohort, we observed an inverse association for bicycling using a ‘soft, comfort seat’ (≥3 vs 0 h/week: SF: FR = 0.75, 95% CI: 0.53–1.05; PRESTO: FR = 0.81, 95% CI: 0.62–1.07) but not a ‘hard, racing-style seat’ (≥3 vs 0 h/week: SF: FR = 1.16, 95% CI: 0.95–1.41; PRESTO: FR = 1.06, 95% CI: 0.89–1.28). Among males with BMI ≥25 kg/m2, associations with bicycling using a ‘soft, comfort seat’ were similar or stronger (≥3 vs 0 h/week: SF: FR = 0.75, 95% CI: 0.45–1.24; PRESTO: FR = 0.73, 95% CI: 0.52–1.03). LIMITATIONS, REASONS FOR CAUTION: Misclassification of PA was likely the most important study limitation because we ascertained PA only once at enrollment using different instruments in each cohort. We would expect misclassification of PA to be non-differential given the prospective study design. Additional weaknesses include the narrow range of PA levels evaluated, reduced precision when stratifying the data by selected covariates, and limited generalizability due to the large percentage of non-Hispanic White participants and restriction of the cohort to pregnancy planners. WIDER IMPLICATIONS OF THE FINDINGS: Further evaluation of the potential deleterious effects of bicycling on male fertility, with additional consideration of the influence of bike seat type and BMI, may be warranted. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by NICHD Grants R21-HD072326, R01-HD086742, R01 HD105863, and R03-HD094117. These funding bodies had no involvement in the: study design; collection, analysis, and interpretation of data; writing of the report; or decision to submit the article for publication. L.A.W. serves as a paid consultant for AbbVie, Inc. and the Bill and Melinda Gates Foundation. She also receives in-kind donations for primary data collection in Pregnancy Study Online (PRESTO) from Swiss Precision Diagnostics (home pregnancy tests) and Kindara.com (fertility apps). All of these relationships are for work unrelated to this manuscript. M.L.E. is an advisor for and holds stock in Legacy, Doveras, VSeat, Hannah, Illumicell, HisTurn, & Next. The other authors have no competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.
- Open Access
Temporal trends in the occurrence, mortality, and cost of brain disorders in Denmark
Background Brain disorders, including neurological and mental disorders, are common and burdensome diseases. Aim To examine temporal trends in occurrence, mortality, and cost of brain disorders in Denmark for the period of 2015–2021. Methods We conducted a nationwide population-based cohort study using individual-level data recorded in the Danish health registries during 2011–2021. We computed the prevalence of any brain disorder and 25 individual brain disorders for each year from 2015 to 2021 and the incidence for the periods 2011–2015 and 2016–2021 by combining hospital diagnoses and filled prescriptions for relevant medications. We computed one-year hazard ratios (HRs) for mortality by comparing individuals with brain disorders to matched controls without. We also calculated attributable direct and indirect costs (i.e., lost productivity) of brain disorders. Results The prevalence of any brain disorder in Denmark was 33.2% in 2015, increasing to 35.2% in 2021. The three most prevalent conditions were depression (13.5% in 2021), sleep disorders (13.5% in 2021), and headache (7.9% in 2021). The incidence rate of any brain disorder was 1,792 and 1,634 per 100,000 person-years in 2011-2015 and 2016-2021, respectively. The one-year HR of mortality for any brain disorder was 5.5 (95% confidence internal [CI]: 5.4; 5.6) for 2011–2015 and 5.3 (95% CI: 5.2; 5.3) for 2016–2021. The total attributable direct costs for individuals with any brain disorder were €7.5 billion in both 2015 and 2021. In 2021, the total attributable indirect costs were highest for depression (∼€3.5 billion) and lowest for neuromuscular disorders (∼€53.5 million). Total indirect costs increased from €17.7 billion in 2015 to €23.2 billion in 2021. In 2021, the total indirect costs were highest for depression (∼€14 billion) and lowest for other neurodegenerative disorders (∼€60 million). Conclusion Brain disorders remain common, with a fivefold higher one-year mortality compared to persons without brain disorders. While total direct costs were similar in 2015 and 2021, total indirect costs increased over this period.
Open AccessTemporal trends in the occurrence, mortality, and cost of brain disorders in Denmark
Background Brain disorders, including neurological and mental disorders, are common and burdensome diseases. Aim To examine temporal trends in occurrence, mortality, and cost of brain disorders in Denmark for the period of 2015–2021. Methods We conducted a nationwide population-based cohort study using individual-level data recorded in the Danish health registries during 2011–2021. We computed the prevalence of any brain disorder and 25 individual brain disorders for each year from 2015 to 2021 and the incidence for the periods 2011–2015 and 2016–2021 by combining hospital diagnoses and filled prescriptions for relevant medications. We computed one-year hazard ratios (HRs) for mortality by comparing individuals with brain disorders to matched controls without. We also calculated attributable direct and indirect costs (i.e., lost productivity) of brain disorders. Results The prevalence of any brain disorder in Denmark was 33.2% in 2015, increasing to 35.2% in 2021. The three most prevalent conditions were depression (13.5% in 2021), sleep disorders (13.5% in 2021), and headache (7.9% in 2021). The incidence rate of any brain disorder was 1,792 and 1,634 per 100,000 person-years in 2011-2015 and 2016-2021, respectively. The one-year HR of mortality for any brain disorder was 5.5 (95% confidence internal [CI]: 5.4; 5.6) for 2011–2015 and 5.3 (95% CI: 5.2; 5.3) for 2016–2021. The total attributable direct costs for individuals with any brain disorder were €7.5 billion in both 2015 and 2021. In 2021, the total attributable indirect costs were highest for depression (∼€3.5 billion) and lowest for neuromuscular disorders (∼€53.5 million). Total indirect costs increased from €17.7 billion in 2015 to €23.2 billion in 2021. In 2021, the total indirect costs were highest for depression (∼€14 billion) and lowest for other neurodegenerative disorders (∼€60 million). Conclusion Brain disorders remain common, with a fivefold higher one-year mortality compared to persons without brain disorders. While total direct costs were similar in 2015 and 2021, total indirect costs increased over this period.
- 21 June 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 39 (8) , 1835-1843
Cervical intraepithelial neoplasia and fecundability: a prospective cohort study
STUDY QUESTION: Is cervical intraepithelial neoplasia (CIN) associated with reduced fecundability, defined as the probability of conceiving per menstrual cycle? SUMMARY ANSWER: Overall, we observed no meaningful association between CIN and fecundability, regardless of surgical status, although a recent diagnosis of moderate or severe CIN might be associated with slightly reduced fecundability for 2 years after diagnosis. WHAT IS KNOWN ALREADY: About 15% of couples experience infertility. Few studies have examined the influence of CIN on fertility, and the results have been inconsistent. No study has investigated the association between fecundability and pathologist-reported CIN diagnoses, particularly with respect to the recency of the specific CIN diagnoses. STUDY DESIGN, SIZE, DURATION: This prospective cohort study included 9586 women trying to conceive. The women were enrolled from 1 June 2007 to 3 February 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women were invited to complete a baseline questionnaire and bimonthly follow-up questionnaires for up to 12 months or until pregnancy occurred. Data on cervical cytologies and biopsies were retrieved from The National Pathology Registry (DNPR), which holds records of all cervical specimens examined in Denmark. Women were categorized based on their most severe diagnosis of CIN: no lesion, other cervical changes, mild CIN (CIN1), or moderate/severe CIN (CIN2+) with or without surgery. To investigate the association between CIN and fecundability, we computed fecundability ratios (FR) and 95% confidence intervals (CI) using a proportional probabilities regression model. We adjusted for age at study entry, partner age, body mass index, smoking status, timing of intercourse, parity, education, number of sexual partners, and household income. MAIN RESULTS AND THE ROLE OF CHANCE: Compared with no lesion, the adjusted FRs (95% CI) for the association between CIN and fecundability were: other cervical lesions, 0.97 (0.91–1.04); CIN1, 1.04 (0.96–1.13); CIN2+ no surgery, 1.00 (0.82–1.22); and CIN2+ with surgery 0.99 (0.89–1.10). The FRs (95% CI) for a recent diagnosis (<2 years) of CIN were 0.98 (0.86–1.11) for other cervical lesions; 1.13 (0.99–1.29) for CIN1; 0.89 (0.62–1.26) for CIN2+ no surgery and 0.91 (0.75–1.10) for CIN2+ with surgery compared with the no lesion group. LIMITATIONS, REASONS FOR CAUTION: In the analyses, we adjusted for several covariates related to the women. However, we had little information on the male partners which could lead to unmeasured confounding as fecundability is a couple-based measure of fertility. Furthermore, a CIN diagnosis may not be constant as it may regress or progress spontaneously; therefore, it is possible that we have misclassified some women, especially women categorized as having normal cells or CIN1. WIDER IMPLICATIONS OF THE FINDINGS: Our results contribute important knowledge to women who are concerned about their future fertility after receiving a CIN diagnosis. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by The Danish Cancer Society (R167-A11036-17-S2). The overall cohorts were funded by the National Institute of Child Health and Human Development (R01-HD086742 and R03-HD094117). The authors report no competing interests. TRIAL REGISTRATION NUMBER: N/A.
- 21 June 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 39 (8) , 1835-1843
Cervical intraepithelial neoplasia and fecundability: a prospective cohort study
STUDY QUESTION: Is cervical intraepithelial neoplasia (CIN) associated with reduced fecundability, defined as the probability of conceiving per menstrual cycle? SUMMARY ANSWER: Overall, we observed no meaningful association between CIN and fecundability, regardless of surgical status, although a recent diagnosis of moderate or severe CIN might be associated with slightly reduced fecundability for 2 years after diagnosis. WHAT IS KNOWN ALREADY: About 15% of couples experience infertility. Few studies have examined the influence of CIN on fertility, and the results have been inconsistent. No study has investigated the association between fecundability and pathologist-reported CIN diagnoses, particularly with respect to the recency of the specific CIN diagnoses. STUDY DESIGN, SIZE, DURATION: This prospective cohort study included 9586 women trying to conceive. The women were enrolled from 1 June 2007 to 3 February 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women were invited to complete a baseline questionnaire and bimonthly follow-up questionnaires for up to 12 months or until pregnancy occurred. Data on cervical cytologies and biopsies were retrieved from The National Pathology Registry (DNPR), which holds records of all cervical specimens examined in Denmark. Women were categorized based on their most severe diagnosis of CIN: no lesion, other cervical changes, mild CIN (CIN1), or moderate/severe CIN (CIN2+) with or without surgery. To investigate the association between CIN and fecundability, we computed fecundability ratios (FR) and 95% confidence intervals (CI) using a proportional probabilities regression model. We adjusted for age at study entry, partner age, body mass index, smoking status, timing of intercourse, parity, education, number of sexual partners, and household income. MAIN RESULTS AND THE ROLE OF CHANCE: Compared with no lesion, the adjusted FRs (95% CI) for the association between CIN and fecundability were: other cervical lesions, 0.97 (0.91–1.04); CIN1, 1.04 (0.96–1.13); CIN2+ no surgery, 1.00 (0.82–1.22); and CIN2+ with surgery 0.99 (0.89–1.10). The FRs (95% CI) for a recent diagnosis (<2 years) of CIN were 0.98 (0.86–1.11) for other cervical lesions; 1.13 (0.99–1.29) for CIN1; 0.89 (0.62–1.26) for CIN2+ no surgery and 0.91 (0.75–1.10) for CIN2+ with surgery compared with the no lesion group. LIMITATIONS, REASONS FOR CAUTION: In the analyses, we adjusted for several covariates related to the women. However, we had little information on the male partners which could lead to unmeasured confounding as fecundability is a couple-based measure of fertility. Furthermore, a CIN diagnosis may not be constant as it may regress or progress spontaneously; therefore, it is possible that we have misclassified some women, especially women categorized as having normal cells or CIN1. WIDER IMPLICATIONS OF THE FINDINGS: Our results contribute important knowledge to women who are concerned about their future fertility after receiving a CIN diagnosis. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by The Danish Cancer Society (R167-A11036-17-S2). The overall cohorts were funded by the National Institute of Child Health and Human Development (R01-HD086742 and R03-HD094117). The authors report no competing interests. TRIAL REGISTRATION NUMBER: N/A.
- Open Access
- 17 March 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 70, 102531
Antipsychotic use during pregnancy and risk of specific neurodevelopmental disorders and learning difficulties in children: a multinational cohort study
- 17 March 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 70, 102531
Open AccessAntipsychotic use during pregnancy and risk of specific neurodevelopmental disorders and learning difficulties in children: a multinational cohort study
- 23 January 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (2) , e207996
Comparative Risk of Major Congenital Malformations With Antiseizure Medication Combinations vs Valproate Monotherapy in Pregnancy
Valproate should be avoided in pregnancy, but it is the most effective drug for generalized epilepsies. Alternative treatment may require combinations of other drugs. Our objectives were to describe first trimester use of antiseizure medication (ASM) combinations that are relevant alternatives to valproate and determine whether specific combinations were associated with a lower risk of major congenital malformations (MCM) compared with valproate monotherapy. We conducted a population-based cohort study using linked national registers from Denmark, Finland, Iceland, Norway, and Sweden and administrative health care data from the United States and New South Wales, Australia. We described first trimester use of ASM combinations among pregnant people with epilepsy from 2000 to 2020. We compared the risk of MCM after first trimester exposure to ASM combinations vs valproate monotherapy and low-dose valproate plus lamotrigine or levetiracetam vs high-dose valproate (≥1,000 mg/d). We used log-binomial regression with propensity score weights to calculate adjusted risk ratios (aRRs) and 95% CIs for each dataset. Results were pooled using fixed-effects meta-analysis. Among 50,905 pregnancies in people with epilepsy identified from 7.8 million total pregnancies, 788 used lamotrigine and levetiracetam, 291 used lamotrigine and topiramate, 208 used levetiracetam and topiramate, 80 used lamotrigine and zonisamide, and 91 used levetiracetam and zonisamide. After excluding pregnancies with use of other ASMs, known teratogens, or a child diagnosed with MCM of infectious or genetic cause, we compared 587 exposed to lamotrigine-levetiracetam duotherapy and 186 exposed to lamotrigine-topiramate duotherapy with 1959 exposed to valproate monotherapy. Pooled aRRs were 0.41 (95% CI 0.24-0.69) and 1.26 (0.71-2.23), respectively. Duotherapy combinations containing low-dose valproate were infrequent, and comparisons with high-dose valproate monotherapy were inconclusive but suggested a lower risk for combination therapy. Other combinations were too rare for comparative safety analyses. Lamotrigine-levetiracetam duotherapy in first trimester was associated with a 60% lower risk of MCM than valproate monotherapy, while lamotrigine-topiramate was not associated with a reduced risk. Duotherapy with lamotrigine and levetiracetam may be favored to treat epilepsy in people with childbearing potential compared with valproate regarding MCM, but whether this combination is as effective as valproate remains to be determined. This study provides Class II evidence that in people with epilepsy treated in the first trimester of pregnancy, the risk of major congenital malformations is lower with lamotrigine-levetiracetam duotherapy than with valproate alone, but similar with lamotrigine-topiramate.
- 23 January 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (2) , e207996
Comparative Risk of Major Congenital Malformations With Antiseizure Medication Combinations vs Valproate Monotherapy in Pregnancy
Valproate should be avoided in pregnancy, but it is the most effective drug for generalized epilepsies. Alternative treatment may require combinations of other drugs. Our objectives were to describe first trimester use of antiseizure medication (ASM) combinations that are relevant alternatives to valproate and determine whether specific combinations were associated with a lower risk of major congenital malformations (MCM) compared with valproate monotherapy. We conducted a population-based cohort study using linked national registers from Denmark, Finland, Iceland, Norway, and Sweden and administrative health care data from the United States and New South Wales, Australia. We described first trimester use of ASM combinations among pregnant people with epilepsy from 2000 to 2020. We compared the risk of MCM after first trimester exposure to ASM combinations vs valproate monotherapy and low-dose valproate plus lamotrigine or levetiracetam vs high-dose valproate (≥1,000 mg/d). We used log-binomial regression with propensity score weights to calculate adjusted risk ratios (aRRs) and 95% CIs for each dataset. Results were pooled using fixed-effects meta-analysis. Among 50,905 pregnancies in people with epilepsy identified from 7.8 million total pregnancies, 788 used lamotrigine and levetiracetam, 291 used lamotrigine and topiramate, 208 used levetiracetam and topiramate, 80 used lamotrigine and zonisamide, and 91 used levetiracetam and zonisamide. After excluding pregnancies with use of other ASMs, known teratogens, or a child diagnosed with MCM of infectious or genetic cause, we compared 587 exposed to lamotrigine-levetiracetam duotherapy and 186 exposed to lamotrigine-topiramate duotherapy with 1959 exposed to valproate monotherapy. Pooled aRRs were 0.41 (95% CI 0.24-0.69) and 1.26 (0.71-2.23), respectively. Duotherapy combinations containing low-dose valproate were infrequent, and comparisons with high-dose valproate monotherapy were inconclusive but suggested a lower risk for combination therapy. Other combinations were too rare for comparative safety analyses. Lamotrigine-levetiracetam duotherapy in first trimester was associated with a 60% lower risk of MCM than valproate monotherapy, while lamotrigine-topiramate was not associated with a reduced risk. Duotherapy with lamotrigine and levetiracetam may be favored to treat epilepsy in people with childbearing potential compared with valproate regarding MCM, but whether this combination is as effective as valproate remains to be determined. This study provides Class II evidence that in people with epilepsy treated in the first trimester of pregnancy, the risk of major congenital malformations is lower with lamotrigine-levetiracetam duotherapy than with valproate alone, but similar with lamotrigine-topiramate.
- Open Access
- 9 October 2023
- Published by Springer Nature in Journal of Gambling Studies
- Vol. 39 (4) , 1765-1780
Comorbidity, Criminality, and Costs of Patients Treated for Gambling Disorder in Denmark
Gambling disorder is associated with increased mental comorbidity, unhealthy lifestyle, criminality, and costs-of-illness, but the available evidence is mainly based on self-reported survey data. We examined the registry-recorded mental and somatic comorbidities, medication use, criminality, and costs-of-illness associated with gambling disorder. We identified individuals diagnosed with or treated for gambling disorder in hospitals or specialized treatment centers during 2013–2017 and matched them by age and sex to general population comparisons. Using individual-level healthcare and socioeconomic registries, we characterized their history of mental and somatic comorbidities, medication use, and criminality. We estimated their cost-of-illness of welfare services (direct) and lowered productivity (indirect) using the human capital approach. We identified 1381 individuals with gambling disorder, primarily young (median age: 34 years) men (87%). Individuals with gambling disorder more frequently than their comparisons had previous hospital-recorded comorbidity [e.g., myocardial infarction (0.8% vs. 0.5%)], medication use [e.g., respiratory system drugs (35.6% vs. 28.6%)], and hospital-recorded or pharmacologically treated mental comorbidity [e.g., depression (39.8% vs. 14.9%)]. Also, sentenced criminality was much more common in individuals with gambling disorder (7.0%) than in comparisons (1.1%). The estimated attributable direct costs were €4.0 M corresponding to €2.9 K per person with gambling disorder, and attributable indirect costs were €17.6 M, corresponding to €13.2 K per person with gambling disorder in 2018. In conclusion, individuals diagnosed with or treated for gambling disorder have a high burden of mental and somatic comorbidities as well as criminality compared with the general population. This needs attention to minimize the societal and personal costs of gambling disorder.
- 9 October 2023
- Published by Springer Nature in Journal of Gambling Studies
- Vol. 39 (4) , 1765-1780
Open AccessComorbidity, Criminality, and Costs of Patients Treated for Gambling Disorder in Denmark
Gambling disorder is associated with increased mental comorbidity, unhealthy lifestyle, criminality, and costs-of-illness, but the available evidence is mainly based on self-reported survey data. We examined the registry-recorded mental and somatic comorbidities, medication use, criminality, and costs-of-illness associated with gambling disorder. We identified individuals diagnosed with or treated for gambling disorder in hospitals or specialized treatment centers during 2013–2017 and matched them by age and sex to general population comparisons. Using individual-level healthcare and socioeconomic registries, we characterized their history of mental and somatic comorbidities, medication use, and criminality. We estimated their cost-of-illness of welfare services (direct) and lowered productivity (indirect) using the human capital approach. We identified 1381 individuals with gambling disorder, primarily young (median age: 34 years) men (87%). Individuals with gambling disorder more frequently than their comparisons had previous hospital-recorded comorbidity [e.g., myocardial infarction (0.8% vs. 0.5%)], medication use [e.g., respiratory system drugs (35.6% vs. 28.6%)], and hospital-recorded or pharmacologically treated mental comorbidity [e.g., depression (39.8% vs. 14.9%)]. Also, sentenced criminality was much more common in individuals with gambling disorder (7.0%) than in comparisons (1.1%). The estimated attributable direct costs were €4.0 M corresponding to €2.9 K per person with gambling disorder, and attributable indirect costs were €17.6 M, corresponding to €13.2 K per person with gambling disorder in 2018. In conclusion, individuals diagnosed with or treated for gambling disorder have a high burden of mental and somatic comorbidities as well as criminality compared with the general population. This needs attention to minimize the societal and personal costs of gambling disorder.
- Open Access
- 18 February 2022
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 114 (6) , 885-894
Medication–Associated Phthalate Exposure and Childhood Cancer Incidence
Background: Human phthalate exposure is widespread through contact with myriad consumer products. Exposure is particularly high through medications formulated with phthalates. Phthalates disrupt normal endocrine signaling and are associated with reproductive outcomes and incidence of some cancers. We measured associations between gestational and childhood medication-associated phthalate exposures and the incidence of childhood cancers. Methods: We identified all live births in Denmark between 1997 and 2017, including both children and birth mothers. Using drug ingredient data merged with the Danish National Prescription Registry, we measured phthalate exposure through filled prescriptions for mothers during pregnancy (gestational exposure) and for children from birth until age 19 years (childhood exposure). Incident childhood cancers were ascertained from the Danish Cancer Registry, and associations were estimated with Cox regression models. Results: Among 1 278 685 children, there were 2027 childhood cancer cases diagnosed over 13.1 million person–years of follow-up. Childhood phthalate exposure was strongly associated with incidence of osteosarcoma (hazard ratio [HR] = 2.78, 95% confidence interval [CI] = 1.63 to 4.75). We also observed a positive association with incidence of lymphoma (HR = 2.07, 95% CI = 1.36 to 3.14), driven by associations with Hodgkin and non-Hodgkin lymphoma but not Burkitt lymphoma. Associations were apparent only for exposure to low-molecular phthalates, which have purportedly greater biological activity. Conclusions: Childhood phthalate exposure was associated with incidence of osteosarcoma and lymphoma before age 19 years. Lingering questions include which specific phthalate(s) are responsible for these associations, by what mechanisms they occur, and to what extent childhood cancer cases could be avoided by reducing or eliminating the phthalate content of medications and other consumer products.
- 18 February 2022
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 114 (6) , 885-894
Open AccessMedication–Associated Phthalate Exposure and Childhood Cancer Incidence
Background: Human phthalate exposure is widespread through contact with myriad consumer products. Exposure is particularly high through medications formulated with phthalates. Phthalates disrupt normal endocrine signaling and are associated with reproductive outcomes and incidence of some cancers. We measured associations between gestational and childhood medication-associated phthalate exposures and the incidence of childhood cancers. Methods: We identified all live births in Denmark between 1997 and 2017, including both children and birth mothers. Using drug ingredient data merged with the Danish National Prescription Registry, we measured phthalate exposure through filled prescriptions for mothers during pregnancy (gestational exposure) and for children from birth until age 19 years (childhood exposure). Incident childhood cancers were ascertained from the Danish Cancer Registry, and associations were estimated with Cox regression models. Results: Among 1 278 685 children, there were 2027 childhood cancer cases diagnosed over 13.1 million person–years of follow-up. Childhood phthalate exposure was strongly associated with incidence of osteosarcoma (hazard ratio [HR] = 2.78, 95% confidence interval [CI] = 1.63 to 4.75). We also observed a positive association with incidence of lymphoma (HR = 2.07, 95% CI = 1.36 to 3.14), driven by associations with Hodgkin and non-Hodgkin lymphoma but not Burkitt lymphoma. Associations were apparent only for exposure to low-molecular phthalates, which have purportedly greater biological activity. Conclusions: Childhood phthalate exposure was associated with incidence of osteosarcoma and lymphoma before age 19 years. Lingering questions include which specific phthalate(s) are responsible for these associations, by what mechanisms they occur, and to what extent childhood cancer cases could be avoided by reducing or eliminating the phthalate content of medications and other consumer products.